

comparison	p.value	CrI
d.Apixaban.Dabigatran	0.478625	NA
-> direct	NA	0.50 (-0.069, 1.0)
-> indirect	NA	0.077 (-1.1, 1.3)
-> network	NA	0.45 (0.049, 0.82)
d.Apixaban.Rivaroxaban	0.766125	NA
-> direct	NA	0.19 (-0.27, 0.63)
-> indirect	NA	0.049 (-0.92, 1.1)
-> network	NA	0.17 (-0.21, 0.56)
d.Dabigatran.Rivaroxaban	0.524000	NA
-> direct	NA	-0.33 (-0.81, 0.18)
-> indirect	NA	-0.024 (-0.97, 0.95)
-> network	NA	-0.28 (-0.63, 0.11)

Supplementary Appendix 7. Node-split model for assessment of inconsistency between direct and indirect comparison in all studies: for each treatment comparison that has both direct and indirect estimates, the analysis provides the mean and credible intervals (the value at 2.5% and 97.5% quantiles) for the direct, indirect and network estimates together with a Bayesian P -value for the related test of inconsistency between the direct and indirect evidence for each treatment comparison. NA, not available; CrI, credible interval.